Economic burden associated with extrapyramidal symptoms in a medicaid population with schizophrenia.

Abstract

No studies have assessed the economic impact of extrapyramidal symptoms due to atypical antipsychotics in schizophrenia. To assess healthcare resource use and medical costs associated with extrapyramidal symptoms in patients with schizophrenia. A retrospective analysis of Marketscan(®) Medicaid Multi-State Database (2004-2009) was conducted. Patients with schizophrenia and newly initiated on an AAP were included. Patients with and without extrapyramidal symptoms were matched using propensity-score matching. Healthcare utilization and costs were assessed in the 12-month follow-up period using logistic and two-part (gamma) regression models. Of 4,621 patients, 583 (12.6 %) had extrapyramidal symptoms. Patients with extrapyramidal symptoms had significantly more schizophrenia-related and all-cause hospitalizations and schizophrenia-related emergency room visits, as well as significantly higher schizophrenia-specific and all-cause total healthcare, inpatient, and prescription drug costs compared to patients without extrapyramidal symptoms. Extrapyramidal symptoms in patients with schizophrenia is associated with increased healthcare resource utilization and higher medical costs.

• Authors: Safiya Abouzaid, Haijun Tian, Huanxue Zhou, Kristijan H Kahler, Michelle Harris, Edward Kim
• Journal: Community mental health journal (Community Ment Health J) Vol. 50 Issue 1 Pg. 51-8 (Jan 2014) ISSN: 1573-2789 [Electronic] United States
• PMID: 23229052 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antipsychotic Agents

Topics

• Adult
• Antipsychotic Agents (adverse effects, economics)
• Basal Ganglia Diseases (chemically induced, economics, epidemiology)
• Drug Costs
• Emergency Service, Hospital (economics, statistics & numerical data)
• Female
• Health Care Costs (statistics & numerical data)
• Health Services (economics, statistics & numerical data)
• Hospitalization (economics, statistics & numerical data)
• Humans
• Male
• Medicaid (economics)
• Referral and Consultation (economics, statistics & numerical data)
• Retrospective Studies
• Schizophrenia (drug therapy, economics, epidemiology)
• United States
• Utilization Review (statistics & numerical data)